Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences (NASDAQ:RNA) with a $33 price target.

May 10, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital reaffirms a Buy rating and a $33 price target on Avidity Biosciences, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating and a specific price target by a reputable analyst like Keay Nakae from Chardan Capital typically signals a strong vote of confidence in the company's future performance. This can positively influence investor sentiment and potentially drive the stock price up in the short term, especially if the market perceives the analysis as well-founded and the price target as achievable.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100